Answers are grounded in this paper and cite their sources.
Preclinical imaging study demonstrates dual mapping of hypoxia and glucose uptake in mouse cancer models, highlighting non-invasive evaluation of hypoxia-modifying drugs.
We have developed a non-invasive imaging protocol for dual assessment of hypoxia and glucose uptake in tumours using oxygen-enhanced MRI and glucoCESL MRI, and test feasibility in GL261 glioblastoma and MOC2 head and neck cancer mouse models. GL261 tumours had a lower non-perfused fraction (p = 0.0015), a trend to higher glucose enhancing fraction (p = 0.07) and a smaller hypoxic glucose refractory fraction (p= 0.021). The normoxic glucose enhancing fraction was significantly larger than the normoxic glucose refractory fraction (p < 0.0001) in both models. These imaging tools will be used to assess the effects of hypoxia modifying drugs.
No takes yet. Share an insight, caveat, or question.
Dickie et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: